Objectives: The relationship of specific psychiatric conditions to adherence has not been examined in longitudinal studies of youth with perinatal HIV infection (PHIV). We examined associations between psychiatric conditions and antiretroviral nonadherence over 2 years.
Background
Due to dramatic improvements in combination antiretroviral therapy (cART) and clinical care, more children with perinatal HIV infection (PHIV) are approaching adolescence and young adulthood. Approximately 3.2 million children under the age of 15 years worldwide are living with HIV infection [1] , and in the United States, 75% of the estimated 10 000 youth with PHIV are now over 15 years old [2] . Near-perfect adherence to ART is recommended to achieve viral suppression, slow disease progression, and to prevent drug resistance and HIV transmission [3, 4] . Adherence is particularly important as youth with PHIV age and become sexually active [5] , assume responsibility for managing their HIV disease, and transition from pediatric to adult care. It is therefore imperative to identify factors associated with nonadherence in order to develop strategies to support ART adherence in youth with PHIV.
Youth with HIV have high rates of psychiatric conditions exceeding those in the general population [6] [7] [8] [9] [10] . Mental health problems co-occur with suboptimal adherence [11] . Behavioral impairment [12] , diagnosis of depression [13] or anxiety, or conduct disorder [12, 14] have been associated with nonadherence, although findings have been mixed [15] [16] [17] .
Adherence is a dynamic behavior that fluctuates [18] . To our knowledge, no studies have examined the relationship of psychiatric conditions to later antiretroviral nonadherence in initially adherent youth with PHIV. However, one study of youth with nonperinatallyacquired HIV showed that among 65 adherent 15-22- year-olds, being depressed and younger was associated with becoming nonadherent over 12 months [13] . In two longitudinal studies of adherence in youth with PHIV, one (n ¼ 138) showed no association between emotional problems and nonadherence [17] ; another (n ¼ 108) did not evaluate psychiatric conditions [19] , neither evaluated predictors of becoming nonadherent. Almost all studies examining mental health and ART adherence have either been cross-sectional [12, [14] [15] [16] , focused on youth with nonperinatally-acquired HIV [13] or did not distinguish between HIV acquisition modes [14] , used one ART adherence measure [12, 14, 16, 17] , or relied on psychiatric information from claims or medical records [14] [15] [16] .
We address previous gaps by using a longitudinal design, a focus on youth with PHIV in the cARTera, well validated measures of psychiatric symptoms, a larger sample size, longer observational period, and multiple adherence measures. The objectives were to evaluate the association between psychiatric symptoms and nonadherence to ART and unsuppressed viral load over time in youth with PHIV; and determine the association between psychiatric conditions at entry, and becoming nonadherent at followup in those who reported being adherent at entry and loss of virologic suppression at follow-up in youth with suppressed viral load at entry.
Methods

Study population
The International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1055 study was a 2-year multisite prospective study that evaluated the prevalence and severity of psychiatric symptoms in youth with PHIV and youth perinatally HIV-exposed, but uninfected, and/or uninfected and living in households with HIV-infected members. Youth were enrolled and followed during 2005-2008, at 29 sites in the United States, including Puerto Rico. Inclusion criteria were: 6-17 years old at enrollment, living with their primary caregiver for at least 12 months, and intelligence quotient at least 70. Youth and caregivers completed assessments at entry, 48 weeks, and 96 weeks. Institutional Review Boards (IRB) at each site approved the study. Staff obtained written informed consent from the caregivers, and assent from youth, as allowed by the site IRBs. Methods are described in detail elsewhere [18, [20] [21] [22] . This analysis included only participants with at least one follow-up visit and at least one visit in which they were prescribed ART, and had adherence and psychiatric symptoms information.
Measures
Nonadherence
We assessed three ART nonadherence outcomes at each study time point: self-reported 3-day recall nonadherence; self-reported past month nonadherence; and unsuppressed viral load. We obtained self-reported adherence through interviews with the youth and/or the caregiver. We used the Pediatric AIDS Clinical Trials Group Adherence Module [23] to measure 3-day recall nonadherence, defined as taking less than 95% of the prescribed ART doses in the past 3 days. To report past month nonadherence, defined as missing a dose during the past month, vs. never, over 1 month ago, or not recalled, participants were asked about when they last missed a medication (ARTor psychotropic medications). Unsuppressed viral load was defined as HIV-RNA above 400 copies/ml based on the most recent HIV-RNA measurement (90 days prior to study visit) abstracted from medical records.
Psychiatric conditions
At each visit, youth reported on their own psychiatric symptoms, and primary caregivers rated their children's symptoms by completing validated, self-administered rating scales based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Primary caregivers completed the Child and Adolescent Symptom Inventory-4R, which assesses psychiatric symptoms in children aged 5-18 years [24] . Children aged 12-18 years completed the Youth's (Self Report) Inventory 4-R (YI-4R) [25, 26] . Children aged 8 to below 12 years completed the Child (Self Report) Inventory-4 [27] -an abbreviated version of the YI-4R -that excludes assessment of oppositional defiant disorder (ODD) and conduct disorder (disruptive behavior disorders) and attention deficit hyperactivity disorder (ADHD) due to concerns about the validity of selfassessment of these symptoms by young children; thus, for children aged 8 to below 12 years, determination of ADHD and disruptive behavior symptomatology was based on caregiver ratings only. Validated Spanish versions were also available. When the symptom score for a given condition reported by either the child or the caregiver equaled or exceeded the threshold necessary for a DSM-IV diagnosis, the child was classified as meeting the symptom cut-off criteria. This analysis focused on the most prevalent conditions in this population, grouped into four domains: any type of ADHD, depression (major depression, or dysthymia), disruptive behavior (ODD or conduct disorder), and anxiety (generalized or separation anxiety). We also created a composite indicator, defined as meeting the symptom cut-off criteria for at least one of these four targeted conditions.
Other covariates
To describe the study population and compare adherent to nonadherent youth, we examined demographic, family, psychosocial, ART use, HIV disease, and mental health treatment characteristics. We considered the following subset of potential confounders that were not on the causal pathway between psychiatric disorders and nonadherence as candidates for inclusion in multivariable models, based on results of prior studies: age, sex, race/ethnicity, annual income, study entry CD4 þ cell count, and protease inhibitor use history.
Statistical analyses
We compared entry characteristics of adherent vs. nonadherent youth for all three nonadherence outcomes, and evaluated differences using chi-square and Fisher's exact tests, as appropriate. We estimated the prevalence of nonadherence and psychiatric conditions at entry, 48 weeks, and 96 weeks. To evaluate associations of each psychiatric condition and each of the three nonadherence outcomes over time, we fitted unadjusted and adjusted logistic regression models using Generalized Estimating Equations (GEEs) to account for within-person correlation in the repeated measures for each participant, assuming an exchangeable covariance structure. We also tested whether the association between psychiatric conditions and nonadherence varied over time, by including an interaction between psychiatric condition and visit. When the P value for the interaction was 0.10 or less, we calculated the predicted probabilities of nonadherence at each time point in those with vs. without the psychiatric condition, adjusting for other covariates. Adjusted models controlled for the subset of variables with P value less than 0.20 in unadjusted models and P value less than 0.10 in multivariable models, with a separate model developed for each nonadherence outcome. In modeling lack of virologic suppression, we conducted sensitivity analyses restricting analyses to youth with 3-day recall adherence data.
To examine the association between each psychiatric condition at entry and incident nonadherence, we restricted analyses to youth who were adherent (or virally suppressed) at entry, and fit unadjusted and adjusted logistic regression models, with covariates in adjusted models selected using the procedures above. We defined incident nonadherence as nonadherence at either week 48 or 96, and loss of virologic suppression as viral load above 400 at either week 48 or 96.
Analyses were conducted using SAS 9.2 (SAS Institute Inc, Cary, North Carolina, USA). Owing to the exploratory nature of the analyses, no corrections were made for multiple comparisons; however, particular attention in interpretation was given to consistencies in the observed findings. The significance criterion was a two-sided P value less than 0.05.
Results
Of 319 youth with PHIV enrolled in P1055, 296 had at least one follow-up visit. Within this group, two participants who reported never receiving ART during the study were excluded. All 294 remaining were evaluable for viral load suppression, 270 had information allowing evaluation of 3-day recall nonadherence, and 272 were included in the evaluation of past-month nonadherence. The sample size for the unsuppressed viral load analyses included data from youth without selfreported adherence information and from visits when youth were not on ART. There were few differences between the 270 youth who were included and 24 youth excluded from the analysis of nonadherence by the 3-day recall. The excluded youth were more frequently older (16) (17) (18) , had lower median CD4 þ cell count, and were not on ART at study entry. For 83% of the excluded youth, the adherence questionnaire was not completed because the participant was not on ART.
Among the 294 participants, about half were girls, most were black or Hispanic, and 52% were between 13 and 17 years old (Table 1) . Demographic characteristics of youth who were nonadherent at entry did not differ from those who were adherent for the 3-day recall and past month nonadherence outcomes; however, youth with unsuppressed viral load more frequently were black, Hispanic, older, or were from a household with an annual household income below $20 000 compared to youth with suppressed viral load at entry. Participants who were nonadherent at entry (for either self-report adherence outcome) more frequently had used protease inhibitors, and participants who were nonadherent by the 3-day recall more frequently had CD4 þ cell counts below 200 cells/ml compared to adherent participants. The proportion using psychotropic medications did not differ by adherence status for either of the self-reported adherence outcomes, but was lower among youth with unsuppressed vs. suppressed viral load.
Prevalence of nonadherence, lack of viral load suppression, and psychiatric conditions
The prevalence of nonadherence at study entry was 14% by 3-day recall, 32% for past month nonadherence, and 38% based on unsuppressed viral load; the prevalence for all three measures remained similar over time (Fig. 1a ).
During study follow-up, 29% reported 3-day recall nonadherence, 54% reported past month nonadherence, and 54% had unsuppressed viral load on at least one occasion. At follow-up, youth who were nonadherent by 3-day or past month recall were significantly more likely than adherent youth to have unsuppressed viral load (e.g. for 3-day recall, 58 vs. 33%, P ¼ 0.01; 60 vs. 33%, P ¼ 0.007 for weeks 48 and 96, respectively), although differences did not attain significance at entry (e.g. for 3-day recall, 45 vs. 34%, P ¼ 0.20).
At entry, 38% met symptom cut-offs for at least one of the targeted psychiatric conditions, 17% for ADHD, 13% for disruptive behavior, 14% for depression, and 18% for anxiety ( Fig. 1b) . Prevalence decreased at later visits for all conditions except for disruptive behavior. Table 2 summarizes unadjusted and adjusted repeatedmeasures logistic regression results for the association of each psychiatric condition and nonadherence, assuming associations remained similar over time. Throughout the study period, youth with anxiety symptoms had 40% lower odds of unsuppressed viral load compared to youth without anxiety. No associations were observed between other psychiatric conditions and nonadherence or unsuppressed viral load.
Psychiatric conditions and nonadherence: Generalized Estimating Equation model results
Covariates independently associated with nonadherence in multivariable models (Table 3) included older age for all three nonadherence measures, and black race for unsuppressed viral load, whereas lower odds of nonadherence were observed for those with higher entry CD4 þ cell count (for 3-day recall), and higher income (for unsuppressed viral load). The associations with unsuppressed viral load, when restricted to youth with adherence information, were similar to those of the full cohort. Sex was considered as a potential covariate for the core models, but was not associated with any outcomes. Figure 2 shows adjusted associations of each psychiatric condition with nonadherence at the three study time points when the assumption of a constant effect over time was not met (interaction P 0.10 
Psychiatric conditions and incident nonadherence and loss of viral load suppression
Among 232 youth who were adherent at entry by 3-day recall, 39 (16%) were nonadherent by 3-day recall at follow-up. Youth with disruptive behavior conditions at entry were more likely than those without to become nonadherent by 3-day recall during follow-up (34 vs. 14%, P ¼ 0.014); this association persisted after adjustment (aOR 3.01, 95% CI 1. 24-7.31) . We observed no significant associations between the other measures of psychiatric conditions at entry and incident nonadherence. Among youth who were adherent in the past month at entry, 33% reported later nonadherence. Twenty-five percent of virologically suppressed youth at entry experienced loss of virologic suppression at later visits. Psychiatric conditions at entry were not associated with development of past month nonadherence or with loss of virologic suppression at follow-up.
Discussion
In this study, youth with PHIV who had depression or disruptive behavior symptoms had greater odds of ART nonadherence at later visits, but not at entry. Youth with ADHD had greater odds of unsuppressed viral load than youth without ADHD symptoms at later visits, but not at entry. Conversely, youth with anxiety had lower odds of unsuppressed viral load compared to youth without anxiety. Although no single psychiatric condition was consistently associated with all three outcomes, observed associations underscore the need for greater clinical attention to prevalent and developing psychiatric conditions, with a purpose of improving adherence and reducing the risk of virologic failure and other adverse HIV disease outcomes as youth with PHIV approach adulthood.
Self-reported nonadherence ranged from 14 to 32% at entry, depending on the measure, and remained similar over time. These estimates are within the 16-60% range found in other studies of US youth with HIV [15, [28] [29] [30] .
Nearly one in three youth in our study reported past month nonadherence, but fewer were nonadherent by 3day recall, similar to studies showing lower nonadherence estimates with shorter recall periods [15, 30, 31] .
There are several potential explanations for associations with nonadherence that we observed at later visits for depression and disruptive behavior, and associations with unsuppressed viral load at later visits for ADHD, but not at entry. As youth become older, the potential deleterious impact of a psychiatric condition on nonadherence may become more acute when adherence to ART must be managed in the context of other stressors emerging in late adolescence, including challenges faced at school, stigma, disclosure of HIV status to peers, and loss of friends and family members to HIV/AIDS. Risk of nonadherence could also be different for youth developing incident psychiatric conditions at later vs. earlier time points. A previous study from our cohort showed that 22% of youth with PHIV who did not meet the symptom cut-off criteria at entry had an incident psychiatric condition during follow-up [8] . The validated rating scales we used to assess psychiatric conditions capture those meeting symptom cut-offs, but were not administered frequently enough to assess short-term fluctuations in psychiatric condition severity, nor do they consider changes in psychiatric treatment over time, each of which could be associated with nonadherence. For ADHD, one review noted that youth with ADHD were more likely than those without to discontinue medication and skip appointments in later adolescence [32] . It is possible that the association between ADHD and lack of viral load suppression, but not self-reported nonadherence, is due to discontinuation of or breaks in medication use at later rather than earlier visits, which are not captured in our self-reported adherence measures.
In contrast to other psychiatric conditions examined, youth with anxiety had 'reduced' odds of unsuppressed viral load over 2 years. Although this finding is counter to a prior study showing that PHIV youth with anxiety had marginally poorer adherence [15] , one study of adults found that presence of anxiety symptoms predicted adherence [33] ; another longitudinal study of pediatric renal and liver transplant recipients showed that anxiety was associated with adherence to immunosuppressive medication [34] . Youth with anxiety may be more vigilant about taking medications, which could lead to viral load suppression. However, our study did not show associations between anxiety and self-reported measures of adherence, which may be due to insufficient statistical power to detect differences in adherence.
Adherence and viral load suppression are highly dynamic, as demonstrated among adults with HIV [18, 35] . Twentyfive per cent of youth with viral load suppression at entry experienced a loss of viral load suppression over 2 years, and up to one-third of youth who were adherent at entry became nonadherent at follow-up, highlighting the need for tools to support adherence and retention in care over time. Adherent youth with disruptive behavior conditions had three-fold greater odds of becoming nonadherent over a 2-year period compared to adherent youth without those conditions. A large cross-sectional study of US youth with PHIV similarly found that youth with conduct problems or general hyperactivity had elevated odds of nonadherence [12] . Engaging and supporting parents and caregivers in management of their children's disruptive behavior conditions, in partnership with mental health and HIV care providers, may be warranted for promoting mental health and ART adherence among youth with these comorbid conditions. Other disorders were not associated with incident nonadherence or loss of viral load suppression in our study possibly due to psychiatric conditions being dynamic over time, particularly during adolescence [36] . Studies in larger samples should determine whether changes in psychiatric condition status are associated with changes in adherence or viral load suppression. Notably, despite a lifetime of HIV disease, two-thirds of adherent youth consistently reported adherence over 2 years, and 75% of suppressed youth were consistently virologically suppressed. Identifying resiliency factors enabling youth to maintain adherence is vital to creating strategies to support adherence [6, [37] [38] [39] [40] .
Older age was an important predictor of nonadherence in our study, consistent with prior research [15, 41, 42] .
Older age may indicate longer illness duration, medication fatigue from years of ART exposure, or accumulated ART resistance [43] . Additionally, adolescents start assuming responsibility for their ARTs and are also more likely to be reporting on their psychiatric condition symptoms and adherence. Adolescent development poses challenges to adherence. As many youth learn their HIV status during identity formation, some may face struggles with how to incorporate HIV disease [44] . Nonadherence may be a way older adolescents assert independence from parents, clinicians, and other authority figures. Youths' efforts to fit in with their peers may include hiding their HIV disease, which may impede adherence [45] . Psychiatric condition symptoms further complicate developmental processes. Additionally, being black and having lower income was each associated with unsuppressed viral load over 2 years, but not with self-reported nonadherence. Racial and economic disparities in virologic and immunologic outcomes and survival have been observed in US adults with HIV [46] , but the underlying mechanisms are less well described. Stress, violence, experiences of discrimination, lower access to or lower quality care, and distrust in the medical system all may contribute to racial and economic disparities we observed [47] .
The present study had limitations. Nonadherence and psychiatric symptoms were assessed through self-report and may be under-reported due to social desirability bias or stigma. To mitigate this, we obtained psychiatric condition data via self-administered questionnaires, and combined caregiver and participant reports. Youth adherence was reported by either the youth or the caregiver. Although prior research has shown reporting discrepancies [48] , associations of psychiatric conditions with nonadherence held in sensitivity analyses adjusting for adherence reporter. The past-month nonadherence measure referred to any medication, precluding the possibility of distinguishing adherence to psychotropic medications from ARTs, which may have resulted in misclassification. Results from this clinic-based sample may not be generalizable to youth with less adequate access to or engagement in medical care. Nevertheless, an important strength is that it is the first study, to our knowledge, to assess relationships between psychiatric conditions and nonadherence in youth with PHIV longitudinally across multiple outcomes and psychiatric conditions using well validated measures.
Results from this study have implications for research and care of youth with PHIV: ongoing screening for psychiatric conditions and ART adherence challenges is essential throughout adolescence and young adulthood. Adherence interventions should address existing and emerging psychiatric comorbidities and their treatment. More research on multifaceted adolescent-friendly clinical, family, and community-based models of care like the Collaborative HIV/AIDS Mental Health Program (CHAMPþ) [39] , which jointly promote mental health and antiretroviral adherence while strengthening family factors, is needed. Our results underscore the need for comprehensive, age-appropriate adherence interventions that promote mental health throughout the transition to adult HIV care. Future research should determine the impact of psychotropic and counseling treatment for current and emerging psychiatric conditions on adherence and viral load suppression as these youth enter young adulthood. As more youth with PHIV in developing countries approach adulthood, longitudinal studies are warranted to examine whether these results are applicable globally.
